https://www.selleckchem.com/pr....oducts/way-100635.ht
The technical, clinical, and internalization success rates in the EUS-ABS and PTBD groups were 97.1% vs 96.6% (P=1.0, 97.1% vs 93.1% (P=.586), and 97.1% vs 75.9% (P=.01), respectively. The adverse event rate was 11.4% vs 27.6% (P=.119). No significant long-term difference was seen in time to recurrent biliary obstruction and survival. Multivariate analysis confirmed EUS-ABS was not an independent risk factor for survival. Similar to PTBD, EUS-ABS can effectively and safely manage DMBO in patients with surgically altered anatomy. Fu
إعجاب
علق
شارك
